- Home
- NCLH vs JAZZ Comparison
NCLH vs JAZZ Comparison
Compare NCLH & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCLH
- JAZZ
- Stock Information
- Founded
- NCLH 1966
- JAZZ 2003
- Country
- NCLH United States
- JAZZ Ireland
- Employees
- NCLH N/A
- JAZZ N/A
- Industry
- NCLH Marine Transportation
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- NCLH Consumer Discretionary
- JAZZ Health Care
- Exchange
- NCLH Nasdaq
- JAZZ Nasdaq
- Market Cap
- NCLH 7.1B
- JAZZ 6.7B
- IPO Year
- NCLH 2013
- JAZZ 2007
- Fundamental
- Price
- NCLH $18.87
- JAZZ $107.51
- Analyst Decision
- NCLH Buy
- JAZZ Strong Buy
- Analyst Count
- NCLH 18
- JAZZ 12
- Target Price
- NCLH $25.65
- JAZZ $183.08
- AVG Volume (30 Days)
- NCLH 13.3M
- JAZZ 730.8K
- Earning Date
- NCLH 07-30-2025
- JAZZ 07-30-2025
- Dividend Yield
- NCLH N/A
- JAZZ N/A
- EPS Growth
- NCLH 120.77
- JAZZ 49.21
- EPS
- NCLH 1.77
- JAZZ 7.51
- Revenue
- NCLH $9,415,989,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- NCLH $8.63
- JAZZ $6.05
- Revenue Next Year
- NCLH $9.68
- JAZZ $4.68
- P/E Ratio
- NCLH $10.68
- JAZZ $14.35
- Revenue Growth
- NCLH 5.57
- JAZZ 5.76
- 52 Week Low
- NCLH $14.21
- JAZZ $95.49
- 52 Week High
- NCLH $29.29
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- NCLH 53.96
- JAZZ 45.65
- Support Level
- NCLH $17.82
- JAZZ $106.56
- Resistance Level
- NCLH $18.63
- JAZZ $109.43
- Average True Range (ATR)
- NCLH 0.64
- JAZZ 2.66
- MACD
- NCLH -0.04
- JAZZ -0.16
- Stochastic Oscillator
- NCLH 56.61
- JAZZ 12.27
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.